Humacyte is proud to announce that the FDA has granted full approval for Symvess™, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular trauma replacement and repair. This approval is a significant milestone in regenerative medicine, offering a new treatment option for patients with severe arterial injuries. Congratulations to our incredible team and partners who made this possible!
Learn more at https://t.co/YOMJ7Qs0oN
See the Prescribing Information, including Boxed Warning: https://t.co/Eg2XmrWjCQ
INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: GRAFT FAILURE
-Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.
CONTRAINDICATIONS
DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries.
WARNINGS & PRECAUTIONS
-Graft Rupture: Vascular graft rupture has occurred in patients treated with SYMVESS. Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia. Follow appropriate procedures for handling and administering SYMVESS.
-Anastomotic Failure: Anastomotic failure has occurred in patients treated with SYMVESS. In clinical studies of SYMVESS, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin. Follow appropriate procedures for handling and administering SYMVESS.
-Thrombosis: Thrombosis has occurred in patients treated with SYMVESS. In clinical trials of SYMVESS, patients received antiplatelet therapy following implantation of SYMVESS to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with SYMVESS.
-Transmission of Infectious Diseases: SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of SYMVESS are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases. Animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, but this does not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. No transmissible agent infections have been reported during clinical testing.
ADVERSE REACTIONS
The most common adverse reactions (≥3%) were thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.
USE IN SPECIFIC POPULATIONS
Pediatric Use: The safety and effectiveness of SYMVESS in pediatric patients (0 to 17 years old) have not been established.
Geriatric Use: Two patients out of the 54 Extremity Group implanted with SYMVESS as a conduit in Study 1 were aged ≥65 years. The number of patients aged ≥65 years was not sufficient to determine whether they responded differently than younger patients to SYMVESS.
#Humacyte #FDAApproval #RegenerativeMedicine #Innovation #Biotech #Firstinclass $HUMA
How can a bioengineered human vessel help your patients?
Come hear us present new data on acellular tissue engineered vessels at #VEITH26#VEITHsymposium:
November 18:
Session 3: Lower Extremity Arterial – Part 1 [Concourse A, Concourse Level]
11:32 AM – Rishi Kundi, MD: Vascular reconstruction in an infected field, a case report
Session 5: Arterial-Venous Access [Concourse A, Concourse Level]
2:22 PM – Young Erben, MD: Phase 3 RCT interim analysis, ATEV vs. AV fistula in women on hemodialysis
2:28 PM – Mohamad Hussain, MD, PhD: Durability and safety across three Phase 3 trials
2:34 PM – Alexis Lauria, MD, RPVI: Long-term human explant evidence of low atherogenic remodeling
November 19:
Session 50: Update on the Clinical Results and the Future of Symvess® in Military and Civilian Settings [Grand Ballroom East, 3rd Floor]
11:50 AM – Dr. Todd Rasmussen, MD, FACS
Then come meet Luna at Booth 312.
More details here: https://t.co/n94MSAHlzl
#VEITH26 #VEITHsymposium #VascularSurgery #DialysisAccess
Q3 marks another important step forward for Humacyte.
Following today’s earnings call, we’re continuing to build commercial momentum for Symvess® while advancing our broader pipeline and laying the foundation for continued growth.
Read more about our Q3 progress, commercial performance and key business updates in today’s press release: https://t.co/n0SLmv6ttM
#Symvess #VascularSurgery #Dialysis #Biotech
Learn more here: https://t.co/NM03kkY9zy.
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/KfniLr7Z8g
INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
BOX WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage.
DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.
WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.
ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.
Thank you, Chicago!
We're grateful to everyone who joined us at the American Heart Association Scientific Sessions.
Thank you to Laura Niklason, M.D., Ph.D., John Alexander, M.D., M.H.S., Alan Kypson, M.D., and Robert Kirkton, Ph.D., for sharing our science, and to the American Heart Association for a great meeting.
Read our release here: https://t.co/OFum6EG6ee
Humacyte's coronary tissue engineered vessel is investigational and has not been approved for sale by the FDA or any other regulatory agency.
#AHA26 #HeartHealth #RegenerativeMedicine
Dr. Blakeslee-Carter just took the stage at the Texas Society for Vascular & Endovascular Surgery Annual Meeting to present “Biologic Conduit for Extremity Arterial Injury.”
The presentation highlighted the evolving role of Symvess® biologic vascular conduits in the treatment of extremity arterial injuries and offered an opportunity to share clinical perspectives with the vascular surgery community.
Thank you to Dr. Blakeslee-Carter for presenting, and to TSVES for bringing together vascular leaders from across the region.
#TSVES #VascularSurgery #VascularTrauma #Symvess
Learn more here: https://t.co/VBTp3ed8hX.
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/uifnWMIgb0
INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
BOX WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage.
DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.
WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.
ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.
Tomorrow, Humacyte is heading to the American Heart Association Scientific Sessions!
Invited Talk by Laura Niklason, MD, PhD
“Engineering the Microenvironment to Accelerate Vascular Regeneration”
Saturday, November 7, 10:15 AM CT
North Hall, Level 3, McCormick Place
Digital Poster by Dr. John Alexander and Dr. Alan Kypson
“First-in-Human Phase 2a Study Design of a Bioengineered Human Coronary Artery for Coronary Artery Bypass Grafting”
Saturday, November 7, 3:57 PM CT
Digital Poster by Dr. Robert Kirkton
“Evaluation of Tissue Engineered Human Vessels in Porcine and Ovine Models of Coronary Artery Bypass Grafting”
Sunday, November 8, 9:15 AM CT
Humacyte's coronary tissue engineered vessel is investigational and has not been approved for sale by the FDA or any other regulatory agency.
#AHA26 #HeartHealth #TissueEngineering #RegenerativeMedicine
Interim Phase 3 V012 data in women on hemodialysis: those assigned to ATEV had 91 more catheter-free days through 12 months vs. AV fistula. *ATEV is investigational and not FDA approved for hemodialysis access; safety and efficacy has not been established. https://t.co/ELwwVXhmK2
We’re heading to American Heart Association Scientific Sessions 2026 with new research highlighting the potential of bioengineered human vessels in coronary artery bypass grafting (CABG).
Humacyte will be featured in three presentations, including an invited talk from Founder and CEO Laura Niklason, M.D., Ph.D., as well as presentations on our investigational coronary tissue engineered vessel (CTEV), spanning preclinical CABG results and the design of our first-in-human Phase 2a study.
Chicago: November 6–9
Learn more about the presentations and the science we’re bringing to AHA: https://t.co/fAHvKcFdLR
The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Our Q3 update is coming.
On November 10 at 8:00 a.m. EST, we’ll report our third quarter 2026 financial results and share the latest business updates.
Save the date and tune in.
View the announcement and webcast details here: https://t.co/sZ47v4rQwQ
Congratulations to The University of Texas Medical Branch on becoming the first system in the Greater Houston metropolitan area to adopt Symvess®, and to the surgical team on a series of firsts of their own.
We’re proud to recognize Dr. Mitchell Cox, Dr. Eric Whittington, and Dr. Channa Blakely on their first Symvess cases, alongside Chief Vascular Resident, Dr. Omar Sahibzada, and Vascular Resident Dr. Annie Cherner, who assisted with the various cases.
We’re excited to celebrate this talented team and another important milestone as experience with Symvess continues to grow across the U.S.
#Symvess #VascularSurgery #BioengineeredTissue #Innovation
Learn more here: https://t.co/8OgpGvh4y5.
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWRso
INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
BOX WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage.
DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.
WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.
ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.
Oklahoma, welcome to the #Symvess® story.
Congratulations to board certified vascular surgeon, Dr. Jones Thomas, and the INTEGRIS Health Baptist Medical Center team on completing the first-ever Symvess case in Oklahoma!
Another state. Another important milestone.
#VascularSurgery
Learn more here: https://t.co/8OgpGvh4y5.
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWRso
INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
BOX WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage.
DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.
WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.
ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.
For many women on hemodialysis, the current standard of vascular care can often fail to meet their needs.
❌ About 50% of women’s AV fistulas fail to mature, compared with 37% in men.
❌ 30% of women rely on a catheter for dialysis, compared with 24% of men.
❌ Women face twice the risk of catheter dysfunction.
That’s why we designed V012, a Phase 3 randomized trial focused only on women.
Today, Thursday, October 22nd at ASN Kidney Week in Denver, Dr. Prabir Roy-Chaudhury of the UNC Kidney Center presents interim results comparing our acellular tissue engineered vessel (ATEV) with the AV fistula in a late-breaking oral session.
#KidneyWk #Nephrology #Hemodialysis #WomensHealth #VascularAccess
Women on dialysis are more likely than men to face fistula failure and catheter dependence. Humacyte’s interim Phase 3 V012 results evaluating ATEV for hemodialysis access in women will be presented at #KidneyWk on Thursday, 10/22, 4:40 PM MT.
Congratulations to Dr. Bo Allen and the team at Ballad Health and Holston Valley Medical Center on Dr. Allen's first Symvess® procedure.
With Dr. Allen joining Dr. Shardul Nagre and Dr. H. Richard Yoon in performing Symvess procedures, Ballad Health continues to expand patient access to innovative treatment options and advance vascular care in the community.
Thank you to the surgeons, nurses and multidisciplinary care teams who made these milestones possible.
#HealthcareInnovation #MedicalExcellence
Learn more here: https://t.co/8OgpGvh4y5.
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWRso
INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage.
DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.
WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.
ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.
Exciting news: Results from our Phase 3 V012 trial of ATEV in women requiring hemodialysis access have been accepted for presentation in a late-breaking oral session at #ASNKidneyWeek 2026, a leading forum for kidney health professionals. #ClinicalResearch#KidneyHealth Read the press release here: https://t.co/Aq7fvxSsUc